| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0062 | 0.9 |